Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in man

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 83-87

  Lyons, D ^a,b   Jackson, S H D ^c   Swift, C G ^c  

^a Department of General Surgery   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; NORADRENALIN; PLACEBO; ANGIOTENSIN RECEPTOR ANTAGONIST; VASOCONSTRICTOR AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; CIRCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPATHETIC TONE; TREATMENT DURATION; VASOCONSTRICTION; VEIN OCCLUSION PLETHYSMOGRAPHY; ADRENERGIC SYSTEM; BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; FOREARM; LOWER BODY NEGATIVE PRESSURE; PLETHYSMOGRAPHY; VASCULARIZATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOREARM; HUMANS; LOSARTAN; LOWER BODY NEGATIVE PRESSURE; MALE; NOREPINEPHRINE; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOMOTOR SYSTEM;

EID: 33845983973     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100023     Document Type: Article

References (36)

1. Bickerton, R.K. & Buckley, J.P. Evidence for a central mechanism in angiotensin induced hypertension. Proc. Soc. Exp. Biol. Med. 106, 834-836 (1961).
2. Reit, E. Actions of angiotensin on the adrenal medulla and autonomic ganglia. Fed. Proc. 31, 1338-1343 (1972).
3. Benjamin, N., Collier, J.G. & Webb, D.J. Angiotensin II augments sympathetically induced venoconstriction in man. Clin. Sci. 75, 337-340 (1988).
4. Lyons, D., Webster, J. & Benjamin, N. Angiotensin II: adrenergic sympathetic constrictor action in humans. Circulation 91, 1457-1460 (1995).
5. Struthers, A.D., Pai, S., Seidelin, P.H., Coutie, W.R.J. & Morton, J.J. Evidence in humans for post synaptic interaction between norepinephrine and angiotensin II with regard to systolic but not diastolic blood pressure. J. Hypertens. 5, 671-676 (1987).
6. Lyons, D., Roy, S., O'Byrne, S. & Swift, C.G. ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Circulation 5, 911-915 (1997).
7. Cleland, J., Semple, P., Hodsman, P., Ball, S., Ford, I. & Dargie, H. Angiotensin II levels, haemodynamics and sympathoadrenal function after low dose captopril in heart failure. Am. J. Med. 77, 880-886 (1984).
8. Cody, R.J., Franklin, K.W., Kluger, J. & Laragh, J.H. Sympathetic responsiveness and plasma noradrenaline during therapy of chronic congestive heart failure. Am. J. Med. 72, 791-797 (1982).
9. Wenting, G.J., Man In't Veld, A.J. & Woittiez, A.J. Effects of captopril in acute and chronic heart failure. Br. Heart J. 49, 65-76 (1983).
10. Nicholls, M.G., Espiner, E.A., Mils, K.B., Swifler, A.J. & Julius, S. Evidence against an interaction of angiotensin II with the sympathetic nervous system in man. Clin. Endoc. 15, 423-430 (1981).
11. Bottcher, M., Behrens, J.K., Moller, E.A., Christensen, J.H. & Andreasen, F. ACE inhibitor premedication attenuates sympathetic responses during surgery. Br. J. Anaesth. 72, 633-637 (1994).
12. Schwieler, J.H., Kahan, T., Nussberger, J. & Hjemdahl, P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am. J. Physiol. 264, E631-E637 (1993).
13. Matsui, H., Makino, N., Yano, K., Nakanishi, H., Hata, T. & Yanaga, T. Modulation of adrenergic receptors during regression of cardiac hypertrophy. J. Hypertens. 12, 1353-1357 (1994).
14. Opie, L.H. & Sack, M.N. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ. Res. 88, 654-658 (2001).
15. Balt, J.C., Mathy, M.J., Pfaffendorf, M. & van Zwieten, P.A. Sympathoinhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats. Fundam. Clin. Pharmacol. 17, 83-91 (2003).
16. Ruiz-Gayo, M., Somoza, B., Bravo, R., Fernandez-Alfonso, M.S. & Gonzalez, C. Chronic losartan treatment decreases angiotensin II-mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats. Life Sci. 67, 3153-3162 (2000).
17. Ma, R., Schultz, H.D. & Wang, W. Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs. Am. J. Physiol. 277(Part 2): H15-H22 (1999).
18. Lewis, E.J., et al. & Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
19. Julius, S., et al. & VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
20. Levy, B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease. Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109, 8-13 (2004).
21. Brooks, D.P. & Ruffolo, R.R. Jr. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J. Hypertens. Suppl. 17, S27-S32 (1999).
22. Nap, A., Belterman, C.N., Mathy, M.J., Balt, J.C., Pfaffendorf, M. & van Zwieten, P.A. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model. J. Renin Angiotensin Aldosterone Syst. 4, 220-227 (2003).
23. Nap, A., Balt, J.C., Pfaffendorf, M. & Zwieten, P.A. No involvement of the AT2-receptor in angiotensin II-enhanced sympathetic transmission in vitro. J. Renin Angiotensin Aldosterone Syst. 4, 100-105 (2003).
24. Damase-Michel, C., Tran, M.A., Montastruc, J.L. & Montastruc, P. Effect of losartan on afferent nerve stimulation. Eur. J. Pharmacol. 355, 125-132 (1998).
25. Johnson, J.M., Rowell, L.B., Niederberger, M. & Eisman, M.M. Human splanchnic and forearm vasoconstrictor responses to reductions of right atrial and aortic pressures. Circ. Res. 34, 15-524 (1974).
26. Abboud, F.M., Eckberg, D.L., Johannsen, U.J. & Mark, A.L. Carotid and cardiopulmonary baroreceptor control of splanchnic and forearm vascular resistance during venous pooling in man. J. Physiol. (London) 286, 173-184 (1979).
27. Ardill, B.L., Bannister, R.G., Fentem, P.H. & Greenfield, A.D.M. Circulatory responses of supine subjects to the exposure of parts of the body below the xiphisternum to subatmospheric pressure. J. Physiol. (London) 193, 57-72 (1967).
28. Bivalacqua, T.J., Dalal, A., Champion, H.C. & Kadowitz, P.J. Role of AT(1) receptors and autonomic nervous system in mediating acute pressor responses to ANG II in anesthetized mice. Am. J. Physiol. 277(Part 1): E838-E847 (1999).
29. Yusuf, S., et al. & CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM -preserved trial. Lancet 362, 777-781 (2003).
30. Dahlof, B., et al. & LIFE Study Group Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
31. Brenner, B.M., et al. & RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
32. Granger, C.B., et al. & CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM -alternative trial. Lancet 362, 772-776 (2003).
33. Lewis, E.J., et al. & Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
34. Whitney, R.J. The measurement of volume changes in human limbs. J. Physiol. 121, 1-27 (1953).
35. Browne, J., Goei, J.S., Greenfield, A.D.M. & Plassaras, G.C. Circulatory responses to stimulated gravitational shifts of blood in man induced by exposure of the body below the iliac crests to sub atmospheric pressure. J. Physiol. (London) 183, 607-627 (1966).
36. Greenfield, A.D.M. & Patterson, G.C. Reactions of the blood vessels of the human forearm to increases in trans mural pressure. J. Physiol. 125, 508-524 (1954).